Biobran (rice bran arabinoxylan) supplement to support breast cancer chemotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study enrolls 96 patients with stage I–III breast cancer at China Medical University Hospital in Taichung, Taiwan. Participants will take 3 grams of Biobran daily for 24 weeks while receiving standard paclitaxel and doxorubicin chemotherapy. Outcomes include chemotherapy-related side effects, quality of life, tumor size and tumor antigen measurements, and routine blood tests. The study compares these measures over the treatment period to characterize any supportive effects of Biobran.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Breast cancer stage I-III

Exclusion Criteria:

* pregnant, lactation, breast recurrence, mental disease, autoimmune disease over hte past 5 years, people who take plant or fungal polysaccharide health supplements

Where it's running

• China Medical University Hospital
  Taichung, Taiwan Recruiting
• China Medical University
  Taichung, Taiwan Not yet recruiting

Study contacts

• Study coordinator: Chong-Kuei Lii, PhD
• Email: cklii@mail.cmu.edu.tw
• Phone: +886916226551

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Capecitabine for MRD-positive, resected ER+/HER2-negative breast cancer

  This Phase 2 trial tests whether taking capecitabine can help people with resected, ER-positive/HER2-negative breast cancer who still have molecular residual disease after standard therapy.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario · NCT07631052

• Meaning-Centered Therapy for Latinos for adults with advanced cancer

  This study tests whether Meaning-Centered Psychotherapy for Latinos (MCP-L) can reduce anxiety and depression and improve quality of life compared with CBT in Spanish-speaking adults with advanced cancer.

  Recruiting Memorial Sloan Kettering Cancer Center · New York, New York and 1 other locations · NCT07225309

• SBRT with intratumoural pembrolizumab before neoadjuvant chemotherapy for high-risk breast cancer

  This study will test whether a short course of focused radiation plus two injections of pembrolizumab into the tumor before chemotherapy helps people with high‑risk invasive breast cancer respond better to treatment.

  Recruiting Phase 2 London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · London, Ontario and 1 other locations · NCT07188246

• Predicting how hormone therapy before surgery affects breast cancer

  This study is testing how hormone therapy before surgery can help people with early-stage breast cancer and what it means for their tumors.

  Recruiting Phase 2 George Washington University · Washington D.C., District of Columbia · NCT06806930

• Meal timing during cancer treatment for Alaska Native and American Indian patients

  This test will see if an 8-hour time-restricted eating schedule during neoadjuvant or adjuvant therapy helps Alaska Native and American Indian adults with rectal or certain breast cancers.

  Recruiting Fred Hutchinson Cancer Center · Anchorage, Alaska · NCT06802172

• Memantine plus structured exercise to protect thinking and memory during breast cancer chemotherapy

  This will test whether memantine combined with a supervised exercise program, memantine alone, or a placebo can prevent or reduce thinking and memory problems in people receiving chemotherapy for stage I–III breast cancer.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06727773

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.